Shots:

• Takeda to get rights to develop and commercialize up to four programs including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy and will also have rights to access MD Anderson’s CAR NK platform
• MD Anderson to get upfront payment and is eligible to receive development and commercial milestones for each target and royalties on sales of any CAR NK product. The companies will conduct a research collaboration to advance these CAR NK programs
• Additionally- Takeda and its partners are evaluating multiple gamma delta CAR-Ts- induced pluripotent stem cell-derived CAR-Ts- CAR-Ts targeting solid tumors- and other next-generation approaches for the improvement of safety- efficacy- and accessibility of first-generation CAR T-cell therapies while plans to advance 5 oncology cell therapies to the clinic by the end of FY20
• CAR NK-cell platform involves isolation of NK cells from umbilical cord blood expressing CARs against specified cancer targets while CD19 CAR NK-cell therapy is been evaluated in P-I/IIa treating patients with relapsed and refractory B-cell malignances with expected enrollment in 2021

Click here to­ read full press release/ article

Ref: Takeda | Image: Takeda